

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHANGES OF  
(1) COMPANY SECRETARY,  
(2) AUTHORISED REPRESENTATIVE  
AND  
(3) AGENT FOR THE ACCEPTANCE OF SERVICE OF  
PROCESS AND NOTICES IN HONG KONG**

The board (the “**Board**”) of directors (the “**Directors**”) of China NT Pharma Group Company Limited (the “**Company**”) announces that due to change of job assignment, Ms. Lai Siu Kuen (“**Ms. Lai**”) tendered her resignation (the “**Resignation**”) as the (1) company secretary of the Company, (2) the authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and (3) the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from 23 October 2020. Ms. Lai confirmed that she has no disagreement with the Board and there are no circumstances related to her Resignation which need to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Company would like to thank Ms. Lai for her contributions to the Company in the past.

The Board is also pleased to announce that Mr. Pang Wing Hong (“**Mr. Pang**”) has been appointed in replacement of Ms. Lai as (1) the company secretary of the Company, (2) the Authorised Representative and (3) the Process Agent with effect from 23 October 2020.

Mr. Pang has over 20 years of experience in financial management, accounting, auditing and corporate finance. He obtained a Bachelor of Business Administration degree, majoring in professional accountancy, from The Chinese University of Hong Kong in 1994 and a Master of Business Administration degree from The University of Adelaide, Australia in 2008. He has been an associate member of the Hong Kong Institute of Certified Public Accountants since 1998 and a fellow member of the Association of Chartered Certified Accountants since 2002. Mr. Pang has been the chief financial officer and company secretary of Miko International Holdings Limited, the shares of which are listed on the Main Board of the Stock Exchange (the “**Main Board**”) (stock code: 1247) since October 2015. Mr. Pang was the chief financial officer of China Green (Holdings) Limited (stock code: 904) from April 2015 to October 2015 and an independent non-executive director of Morris Holdings Limited (stock code: 1575) from April 2019 to July 2020, both of which are listed on the Main Board.

By Order of the Board  
**China NT Pharma Group Company Limited**  
**Ng Tit**  
*Chairman*

Hong Kong, 23 October 2020

*As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao and Mr. Pan Fei.*